DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Pendred syndrome — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePendred syndrome maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pendred syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
potassium inwardly rectifying channel subfamily J member 10 (KCNJ10) — KCNJ10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet spmdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9MA5 · 3.18 Å · ligand SPERMINE (SPM). Experimental structure, not a prediction.
What the evidence adds up to
Pendred syndrome is an autosomal recessive disorder defined by congenital sensorineural deafness, goiter, and impaired iodide organification. It is caused by mutations in the PDS gene, which encodes pendrin, a chloride/iodide transporter expressed in the thyroid, inner ear, and kidney. In a 2005 study of three siblings from a nonconsanguineous Sicilian family, all three presented with the classic triad and a positive perchlorate discharge test. Two siblings were compound heterozygous for mutations in the coding region: one allele carried a novel frameshift mutation (890delC, FS297>302X), and the other a previously described transition (1226G>A, R409H). The third sibling had only the frameshift mutation identified; no mutation was found on the other allele, suggesting an unidentified mutation in a regulatory or intronic region, or a distinct pathogenic mechanism. Functional studies showed these mutants lose pendrin’s ability to mediate iodide efflux.
A 2004 case report describes a young girl with Pendred syndrome and a euthyroid state who was found on histopathology to have follicular carcinoma of the thyroid, requiring re-tailoring of management. This indicates that thyroid malignancy can occur in Pendred syndrome, though the report does not provide incidence rates or sample sizes.
A 2024 review summarises that while typical mutations underlying the syndrome and their cellular implications have been elucidated, many unknowns remain. Diagnostic approaches and clinical guidelines have been refined, but effective treatment modalities remain elusive. The review states plainly that despite enhanced understanding of the disease, the development of targeted and efficacious therapies for Pendred syndrome has yet to be achieved. No drug therapy is mentioned in any of the abstracts.
What is still missing is any proven pharmacological treatment for Pendred syndrome. The 2024 review explicitly notes that further research is warranted to bridge existing knowledge gaps and find treatment. No clinical trials of drug repurposing for Pendred syndrome are described in these abstracts. The absence of a therapy means that management remains limited to addressing goiter and hearing loss symptomatically, and no patient stratification or trial design for a drug intervention has been reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Thyroid · 2005 · 27 citations
Molecular Analysis of the <i>PDS</i> Gene in a Nonconsanguineous Sicilian Family with Pendred's Syndrome
AbstractOBJECTIVE: The autosomal recessive Pendred's syndrome is defined by congenital sensorineural deafness, goiter, and impaired iodide organification. It is caused by mutations in the Pendred's syndrome (PDS) gene that encodes pendrin, a chloride/iodide transporter expressed in the thyroid, the inner ear, and the kidney. In this study we performed clinical and molecular analyses in three siblings from a nonconsanguineous Sicilian family who presented with the clinical features of Pendred's syndrome. PATIENTS AND MOLECULAR ANALYSES: In two sisters and one brother, the clinical diagnosis of Pendred's syndrome was established based on the findings of sensorineural hearing loss and large goiters. Thyroid function tests, perchlorate discharge tests, thyroid ultrasound, and scintigraphy were performed in all affected individuals. Exons 2 to 21 of the PDS gene were amplified by polymerase chain reaction (PCR) and both strands were submitted to direct sequence analysis. RESULTS: The clinical diagnosis of Pendred's syndrome was supported by a positive perchlorate discharge test in the three afflicted siblings. Direct sequence analysis of the PDS gene revealed that all three harbored one allele with a novel mutation 890delC leading to a frameshift mutation and premature stop codon at position 302 (FS297 > 302X). On the other allele, two of the siblings had a previously described transition 1226G > A, which results in the substitution of arginine by histidine at position 409 (R409H). In the index patient, no mutation could be identified on the other allele. In functional studies, these mutants lose the ability of pendrin to mediate iodide efflux. CONCLUSIONS: All three patients included in this study presented with the classic Pendred syndrome triad. Two siblings were compound heterozygous for mutations in the coding region of the PDS gene. The third individual could have an unidentified mutation in a regulatory or intronic region of the PDS gene, or an identical phenotype caused by distinct pathogenic mechanisms.
AbstractPendred syndrome is a rare inherited disorder of bilateral sensorineural deafness with goitre. Presence of follicular carcinoma thyroid makes it even rarer. A case of a young girl is described with the features of Pendred syndrome and euthyroid state. Follicular carcinoma of thyroid was detected on histopathology requiring re-tailoring of the management.
Problemy Pielęgniarstwa · 2024 · 0 citations · open access
Pendred syndrome: Advances in diagnosticsand unresolved therapeutic challenges
AbstractPendred syndrome remains a condition characterised by numerous complexities and unresolved aspects despite significant advancements in understanding its aetiology and clinical manifestations. The aim of the study was to summarise the latest reports on this autosomal recessive disorder. While typical mutations underlying the syndrome and their implications on cellular function have been elucidated, there are still many unknowns surrounding the disease. Although a typical clinical profile of Pendred syndrome patients has been established, ongoing research continues to uncover new pathomechanisms attributed to these mutations. While diagnostic approaches and clinical guidelines have been refined, effective treatment modalities remain elusive. Despite our enhanced understanding of the disease, the development of targeted and efficacious therapies for Pendred syndrome has yet to be achieved. In summary, while progress has been made in unravelling the intricacies of Pendred syndrome, further research is warranted to bridge existing knowledge gaps and find treatment for this disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
